{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T19:38:16Z","timestamp":1782157096347,"version":"3.54.5"},"reference-count":38,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2020,10,31]]},"DOI":"10.5582\/ddt.2020.03073","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T22:05:59Z","timestamp":1603922759000},"page":"218-225","source":"Crossref","is-referenced-by-count":20,"title":["Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice"],"prefix":"10.5582","volume":"14","author":[{"given":"Junkichi","family":"Kanda","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacotherapy, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Furukawa","sequence":"additional","affiliation":[{"name":"General Health Medical Center, Yokohama University of Pharmacy, Yokohama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Izumo","sequence":"additional","affiliation":[{"name":"General Health Medical Center, Yokohama University of Pharmacy, Yokohama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taketoshi","family":"Shimakura","sequence":"additional","affiliation":[{"name":"Niigata Bone Science Institute, Niigata, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Niigata Bone Science Institute, Niigata, Japan."},{"name":"Division of Orthopedic Surgery, Niigata Rehabilitation Hospital, Niigata, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki E.","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Niigata Bone Science Institute, Niigata, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Wakabayashi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacotherapy, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","unstructured":"1. Raisz LG. Physiology and pathophysiology of bone remodeling. Clin Chem. 1999; 45:1353-1358."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science. 2000; 289:1508-1514.","DOI":"10.1126\/science.289.5484.1508"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Heilmeier U, Patsch JM. Diabetes and bone. Semin Musculoskelet Radiol. 2016; 20:300-304.","DOI":"10.1055\/s-0036-1592366"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hothersall EJ, Livingstone SJ, Looker HC, Ahmed SF, Cleland S, Leese GP, Lindsay RS, McKnight J, Pearson D, Philip S, Wild SH, Colhoun HM. Contemporary risk of hip fracture in type 1 and type 2 diabetes: a national registry study from Scotland. J Bone Miner Res. 2014; 29:1054-1060.","DOI":"10.1002\/jbmr.2118"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007; 166:495-505.","DOI":"10.1093\/aje\/kwm106"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Melton LJ 3rd, Leibson CL, Achenbach SJ, Therneau TM, Khosla S. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res. 2008; 23:1334-1342.","DOI":"10.1359\/jbmr.080323"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Weber DR, Haynes K, Leonard MB, Willi SM, Denburg MR. Type 1 diabetes is associated with an increased risk of fracture across the life span: a population-based cohort study using The Health Improvement Network (THIN). Diabetes Care. 2015; 38:1913-1920.","DOI":"10.2337\/dc15-0783"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Watts NB. Adverse bone effects of medications used to treat non-skeletal disorders. Osteoporos Int. 2017; 28:2741-2746.","DOI":"10.1007\/s00198-017-4171-4"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O&apos;Neill MC, Zinman B, Viberti G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355:2427-2443.","DOI":"10.1056\/NEJMoa066224"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care. 2007; 30:1574-1576.","DOI":"10.2337\/dc06-2606"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008; 168:820-825.","DOI":"10.1001\/archinte.168.8.820"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochelli\u00e8re R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM. Comparison of pioglitazone <i>vs<\/i> glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008; 299:1561-1573.","DOI":"10.1001\/jama.299.13.1561"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, Jilka RL. Inhibition of Osf2\/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma 2. J Cell Biochem. 1999; 74:357-371.","DOI":"10.1002\/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kanda J, Izumo N, Kobayashi Y, Onodera K, Shimakura T, Yamamoto N, Takahashi HE, Wakabayashi H. Effect of the antidiabetic agent pioglitazone on bone metabolism in rats. J Pharmacol Sci. 2017; 135:22-28.","DOI":"10.1016\/j.jphs.2017.08.004"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Tsukiyama K, Yamada Y, Yamada C, Harada N, Kawasaki Y, Ogura M, Bessho K, Li M, Amizuka N, Sato M, Udagawa N, Takahashi N, Tanaka K, Oiso Y, Seino Y. Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol Endocrinol. 2006; 20:1644-1651.","DOI":"10.1210\/me.2005-0187"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Zhong Q, Itokawa T, Sridhar S, Ding KH, Xie D, Kang B, Bollag WB, Bollag RJ, Hamrick M, Insogna K, Isales CM. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab. 2007; 292:E543-E548.","DOI":"10.1152\/ajpendo.00364.2006"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kern M, Kl\u00f6ting N, Niessen HG, Thomas L, Stiller D, Mark M, Klein T, Bl\u00fcher M. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS One. 2012; 7:e38744.","DOI":"10.1371\/journal.pone.0038744"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013; 28:2-17.","DOI":"10.1002\/jbmr.1805"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab. 2008; 34:S65-S72.","DOI":"10.1016\/S1262-3636(08)73397-4"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Nauck M, St\u00f6ckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986; 29:46-52.","DOI":"10.1007\/BF02427280"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Holst JJ, Knop FK, Vilsb\u00f8ll T, Krarup T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care. 2011; 34:S251-S257.","DOI":"10.2337\/dc11-s227"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Miyawaki K, Yamada Y, Ban N, <i>et al.<\/i> Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 2002; 8:738-742.","DOI":"10.1038\/nm727"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med. 1996; 2:1254-1258.","DOI":"10.1038\/nm1196-1254"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Turton MD, O&apos;Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996; 379:69-72.","DOI":"10.1038\/379069a0"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2012; 14:1040-1046.","DOI":"10.1111\/j.1463-1326.2012.01662.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Su B, Sheng H, Zhang M, Bu L, Yang P, Li L, Li F, Sheng C, Han Y, Qu S, Wang J. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists&apos; treatment: a meta-analysis of randomized controlled trials. Endocrine. 2015; 48:107-115.","DOI":"10.1007\/s12020-014-0361-4"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011; 34:2474-2476.","DOI":"10.2337\/dc11-1099"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Driessen JH, van den Bergh JP, van Onzenoort HA, Henry RM, Leufkens HG, de Vries F. Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study. Diabetes Obes Metab. 2017; 19:421-428.","DOI":"10.1111\/dom.12843"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Guest PC, Rahmoune H. Characterization of the <i>db\/db<\/i> mouse model of type 2 diabetes. Methods Mol Biol. 2019; 1916:195-201.","DOI":"10.1007\/978-1-4939-8994-2_18"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Terawaki Y, Nomiyama T, Kawanami T, Hamaguchi Y, Takahashi H, Tanaka T, Murase K, Nagaishi R, Tanabe M, Yanase T. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury. Cardiovasc Diabetol. 2014; 13:154.","DOI":"10.1186\/s12933-014-0154-3"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Ide M, Sonoda N, Inoue T, Kimura S, Minami Y, Makimura H, Hayashida E, Hyodo F, Yamato M, Takayanagi R, Inoguchi T. The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation. PLoS One. 2020; 15:e0228750.","DOI":"10.1371\/journal.pone.0228750"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Zhang Y, Fava GE, Wu M, Htun W, Klein T, Fonseca VA, Wu H. Effects of linagliptin on pancreatic \u03b1 cells of type 1 diabetic mice. J Endocr Soc. 2017; 1:1224-1234.","DOI":"10.1210\/js.2017-00253"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Takahashi H, Nomiyama T, Terawaki Y, Horikawa T, Kawanami T, Hamaguchi Y, Tanaka T, Motonaga R, Fukuda T, Tanabe M, Yanase T. Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice. Biochem Biophys Rep. 2019; 18:100640.","DOI":"10.1016\/j.bbrep.2019.100640"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Michurina SV, Ishenko IJ, Klimontov VV, Archipov SA, Myakina NE, Cherepanova MA, Zavjalov EL, Koncevaya GV, Konenkov VI. Linagliptin alleviates fatty liver disease in diabetic <i>db\/db<\/i> mice. World J Diabetes. 2016; 7:534-546.","DOI":"10.4239\/wjd.v7.i19.534"},{"key":"35","unstructured":"35. Vidal B, Pinto A, Galv\u00e3o MJ, Santos AR, Rodrigues A, Casc\u00e3o R, Abdulghani S, Caetano-Lopes J, Ferreira A, Fonseca JE, Canhao H. Bone histomorphometry revisited. Acta Reumatol Port. 2012; 37:294-300."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Recker RR, Kimmel DB, Dempster D, Weinstein RS, Wronski TJ, Burr DB. Issues in modern bone histomorphometry. Bone. 2011; 49:955-964.","DOI":"10.1016\/j.bone.2011.07.017"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Xie D, Zhong Q, Ding KH, Cheng H, Williams S, Correa D, Bollag WB, Bollag RJ, Insogna K, Troiano N, Coady C, Hamrick M, Isales CM. Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone. 2007; 40:1352-1360.","DOI":"10.1016\/j.bone.2007.01.007"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, Tanaka K, Drucker DJ, Seino Y, Inagaki N. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology. 2008; 149:574-549.","DOI":"10.1210\/en.2007-1292"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/14\/5\/14_2020.03073\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T03:50:59Z","timestamp":1604721059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/14\/5\/14_2020.03073\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,31]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2020.03073","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,31]]}}}